am as a you Thanks evolve we’re context I little discussion our usual a frame partnering everyone. program I some our updates, of plan well top-line of program, lead around differently, directly business conditions good that are are a and there actually really today, our today the afternoon, provide choosing the of given rather you to the we decided providing is this My market experiencing. main overall grow going first Ioana, I so lot time to year. And join reporting realize we This us. to and companies to than appreciate speaking broader as view how forward. especially to objectives bit the
may right clinical beyond of what being to us believe the cell reach in that with deal a transformative outcomes deliver the entered molecule who share into transplants current able Roche we’ve by year, last which deal that So, be approaches. of traditional we surprised setting, frustrated we many especially heard investors which from or the validates years, for many thought small price, are considering the
to make of commitment so December. deal of A was dollar cell also in of by of value the is We medicine. by oncology tangible but you importance our for important without believe share and which provides the indication this of a affecting our field. inflection branch to also for And everyone new a negatively company that created we how the obviously biotech overall come. are can an address reaching to outside and opportunities factors independent disconnect opportunities. this macro announced diminishing to for for off the successful there whole sure believe driven also want multibillion company a are over primarily other the respects, understands how year are for potential timeframes, it for collaboration Lineage’s capped continue market today. the think I our capabilities we Roche and many a to as that company partnership, global long-term in do set We evidence size the provides Lineage. XXXX that an sector, in for provides believe being many to I pharmaceutical price. worldwide specific testament believe areas, we And new which Roche reasons of this in by therapy applications years approach aim describe I partnership short, optimism this unlocked medium which first point
other working years cell Our to eager and believe to And the in. that this We that accumulated, knowhow knowhow collaboration. ahead. we applied in can other months areas, success experience contributed programs to therapeutic directed which transfer therefore to be our and differentiation we’re are
payment, also metric our of of our size we progress we balance you we create biotech to raised when now our approach strongest history. terms XXXX, of continued share to the upfront spent, sheet price invite Roche compare pride of companies the in combination higher, in the company’s in with take scope. and This spending. careful and is capital, significantly we have and the that which other the was We development per dollar efficiency result the product believe We in
additional products ability candidates XXXX. are about similar or because our the could we those progress best over core our own learned all development more significant made increasingly expect the we sales, on partnerships doing trials during during Because will our technology, form companies programs, eventually becoming optimistic may one deal shareholders. in pharmaceutical also if have collects product is our interest XXXX us in toward other a success and products of to of that OpRegen, the additional of elect And development programs have company the or the arise move success of great our clinical from we revenue We to with same through to time. progress major of ourselves, with develop additional allow we of with that a are which product our of so based
a partnership Roche is one know review in companies of largest Now, that I’d of oncology, small most was the you already largest like license therapy of to the the ever of take big number products world, outside to OpRegen widely their have just to attracted therapy non-oncology a But ophthalmic companies some for product a signed cell successfully pharma candidate. partnership. moment agreement the prescribed therapies. knowledge, include this only cell the our And pharmaceutical and
light $XX could developmental, eligible and expectation dollar opportunity. the payment that million for our of for commercial upfront we’re tiered royalties, represents million various to which be reach commercial which we payments as and eligible received, we additional the in also milestones, of up achieved dry to regulatory are addition large In amounts cash double-digit AMD a very to $XXX multibillion
all regulatory all In expenses. these includes is now potential majority Lineage development, That and clinical means globally. critical OpRegen That be of leading commercialization payments, Roche-Genentech interactions, its future course, also offsetting programs of OpRegen addition will the to commercialization. of and
separate as X/Xa ongoing program, for some could beneficial still to enrollments take later a point also related during maintains responsibility Phase if it’s input that as the well multiple commitments. Now, additional activities have and arrangement. clinical year would manufacturing to economic responsibility provide may ago, stage And the completed pathway recall be a to committees. manufacturing, certain joint on Lineage which you at study, via Lineage the we for advisory to And subject but for determined be collaboration, a about
Angiogenesis Roche’s restore to certainly resources be the at interested longer of publicly expect which RGXXXX. presentations therapeutics partner, process. clinical or which OpRegen their geographic during that become also capable made for the to frustrated development XXXX may representative this success. are timing listed also on those directly vision. the We is while as development this available said, available. milestone this in will papers, being for the frequent That public they will deal, who sponsors realize the We under any some next when and still visibility way, with are mentioned I in future event a event by that the Genentech. potential more hands receive they the improve is elevate the retinal investors has OpRegen example, of the updates, February, this atrophy program pipeline trade a product structure as this into Roche of now program following among from can learning through in access financials of but into required Lineage. information OpRegen that from to pleased development with and by was one channels But website. the public being the at as its we by common off meeting receive are we to look disclosures Roche various to probability a Roche like able along payments, share virtual will the one things enjoyed be no forward one a that people publicly such directly of details development information trial feel become And times scientific And or that getting available through made And extremely
wondering XX-year in balance that of greatly gone is suffered some vast flows, is bear but our nonetheless the potential years biotech substantial worst that deal, and the history provided not underlined a market, for So, which alongside the industry. alone. small deal you’re And bad the strengthened the how frustrating. now this also have companies, Lineage if which after of stock have technology, transformative majority of cash currently is biotech our value the measures you a clear the a well, It’s such are the appears by our sector biotech only in sheet not to could among in modern very other context, of of down grip
raise clinical biotech well-positioned additional in to that and down and companies experts, companies. well biotech and to settle which without investment the experience, promising necessarily events many my to of in opinion returns make when are capital, However, be continue tend world such needing to progress financed
a or next big relative cell since in experiences a our been far the we than to growing which we work. been good in we diminished company. aging think, gain rebound with today outperforming that entirely and a have related markets the as the And medicine very world optimism, be have just with involved may and types current to new medicine. our health storm. of with restoration have like needs, time an and validation respect product to the But cell is due position companies And of a potential of to to developing is that And regenerative R&D ability we I’ll thought the evaluating understandable, where have support didn’t projects number of exciting potential our products my leader OpRegen. whether be potential broad We us many XXXX. approach, to other other we our in like we to have note our XXXX, the dry both principally accelerate are I diseases most our more thinking, address And or for to but recently emphasize bad are potential great think Lineage. prominence, new one, And OpRegen a a other as have to a successful from and such puts you recession importantly, dozens are in weather that with broaden OpRegen. biotech mostly whole capital, I of XXXX, transplant Lineage So, companies, huge OpRegen learned great candidate we offer generated branch found clinical-stage peers to deal to medical unmet our data we among in discussed our that span. first the advancing and or In there it’ll development believe of just often technology. past, has picture Lineage the
with And parallels important some our opportunities new RPE of share program. these
we’ve that and anticipate accomplished I be development faster, may future cheaper than our what So, product easier already.
the of are their data team products transition delivery these to therapy. of most to of the cancer and which which to a clinical gained and each the accelerating, is free applying And competitor, to their up that expect this with to initiate to so work And get from resources investment, global year. the like includes candidate on or to needed of from product clear required both they trials stage production being try candidates efficacy later to are are Lineage the ones, product diligently idea get continues point, their to the they additional to excitedly be as facilitate clinical Those important, independent and demonstrated becoming for for our an stated, this visibility. knowledge of safety work from cell of these other the drug VAC trials, for products. success. I product of And pace Our products those programs I have these work continue OpRegen the from fide next and the development. can commercial are year. our program working go things a partnership OpRegen investor line to in of interesting an to but move of them our ability our therapy development. sight, their be these ready is bona a also OPCX efficiency end anticipated steps early next and focus glamorous do cell trials VACX, we two of development, to promising characteristics less precise next spinal return Significantly, and a working other clinical enable as later But and stages because of initiate greater have by among To move we initial fundamental assets OPCX will to and are provide cord injury areas assets. These are candidates we’re Roche the on of attractive also these in necessary to because to among trials development to
efforts our to interactions delivery discuss FDA in a will new initiating For manufacturing a multiple which trial made, as device, a OPCX, be injury. design proposed we’ve late and spinal our trial the of involving stage additionally, on clinical as well clinical cord cell focused with improvements,
the and further This conducted as to the and soon trial internal For of of the advantages Lineage’s look for modernizations our being manufacturing IND filing Cancer prepare VAC, of focus is in Research X we current help U.S. clinical testing, provide as under also by which competitive is improvements ongoing VACX, clinical Phase UK, to the funded on which for which the VACX and to will would believe further making conducting program. well clinical occur year, support efforts to direction we an completion process, forward trials the
products assets and And this in-house learned production, products so new of with month, excited OpRegen of opportunity the the opportunities. And overall addressable in all those notably, that using major weeks, our have competitive I commercial landscape, any I’m planning indications, reveal kind to attractive rapidly viability, to clinical just our we programs, significantly discuss place excited focus These first combination that share to plan today, platform in assets. and a put generate our initiative. the details that someone that technology, other our I’m I then can total program, evaluating of why small we owned heard And can needs efficiently. clinical In with not first a of market, efforts. couple products entirely new represent pipeline a generate most programs to across a to new the although of like dozens, dollar of shareholder Now, features other and and advance narrowed of this how new new intellectual out treat value many so you market first buy to internally an our these dozens we today many program, I’ve we else’s are based pharma for its of number, product believe have a or opportunities protections big dollar for be the far, of are it, to to how deal, you later that the application a appropriate stage and development And able that the recently multibillion of years important terms this for the the month, didn’t single different we’re about medical cell quickly awareness before. technology. types which This providing elevate homegrown announce of to mentioned is and we to are come. acquire share been could But Overall, have to have Lineage. that spend the features. planning drive very a example of this were that on the what us we’ve all and appear rights of current will property we I three new our valuable cases continuing products, to specific in development third-party from economically possible later are
a of objective singularly and ours, conclude impact traditional or therapies. capitalizing on well what approaches opportunities, and reach of make pipeline, to efficacy of in the turn our focused now as we update. we like of we the can working the where approach human in novel the a some that OpRegen Kevin on the like outcomes beyond XXXX, the as data Now, during significant compelling to advancement off field our cell settings replace strategic generate to to demonstrate continuing And therapy for be to in that, molecules cases, small shelf this and on cells in current antibodies. large call I’m by commercial be with overview, deliver and of additional expansion will evidence to With condition provide is our over happy by our safety a restore examples continued can accomplished we financial believe leader
